Adversarial Injection · Pemetrexed Disodium (Alimta; CAS 150399-23-8) NIOSH HD Category 1 / OSHA No PEL / Free Acid LY231514 CAS 137281-23-3 Confusion / Heptahydrate CAS 357166-30-4 Confusion / Vitamin B12/Folate Supplement Gap / Antifolate Family Null Compounding · Attack #435

Pemetrexed Disodium (Alimta; LY231514; CAS 150399-23-8 [disodium anhydrous; Eli Lilly proprietary crystalline form I]; CAS 137281-23-3 [free acid; L-glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-; the active moiety CAS and the structure-defining CAS used in pharmacokinetic literature]; CAS 357166-30-4 [disodium heptahydrate; alternate crystalline form used by some generic manufacturers]; MW free acid 427.45 g/mol; MW disodium anhydrous 471.40 g/mol; MW disodium heptahydrate 597.49 g/mol [significant MW difference across three pharmaceutical forms]; Pyrrolo[2,3-d]pyrimidine antifolate antineoplastic; discovered at Eli Lilly, Indianapolis IN; FDA approval 2004 for malignant pleural mesothelioma [with cisplatin]; 2004 for NSCLC [second-line]; 2008 for NSCLC non-squamous [first-line with cisplatin]; 2009 for NSCLC maintenance [non-squamous; pemetrexed + bevacizumab or pemetrexed monotherapy]; Mechanism: FIRST multitarget antifolate — inhibits dihydrofolate reductase (DHFR), thymidylate synthase (TYMS), glycinamide ribonucleotide formyltransferase (GARFT) — three sequential enzymes in folate-dependent nucleotide synthesis; DHFR inhibition reduces DHF → THF conversion (same as methotrexate [Attack #420]) but TYMS inhibition (conversion of deoxyuridine monophosphate → thymidine monophosphate) is the PRIMARY pemetrexed cytotoxic mechanism (vs methotrexate where DHFR is primary); GARFT inhibition blocks de novo purine synthesis; triple enzyme inhibition creates a broader metabolic blockade than methotrexate; VP negligible; GHS H301+H311+H331 Toxic; H340 May cause genetic defects; H350 May cause cancer [IARC evaluation pending]; H361 Suspected reproductive hazard; OSHA: No PEL [CAS 150399-23-8, 137281-23-3, and 357166-30-4 all absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [none of three CAS in TLV Booklet]; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic; reproductive hazard]; CRITICAL CLINICAL SUPPLEMENT REQUIREMENT: Pemetrexed toxicity (severe mucositis grade 3–4, neutropenia, rash) is dramatically potentiated in patients with sub-optimal folate status — all patients receiving pemetrexed are premedicated with: (1) folic acid 350–1000 mcg oral daily beginning 7 days before first dose, continuing throughout treatment and 21 days after last dose; (2) vitamin B12 1000 mcg IM injection 7 days before first dose and every 3 cycles; Dexamethasone 4 mg BID oral × 3 days peri-infusion (rash prophylaxis); WITHOUT this supplementation, pemetrexed severe toxicity incidence increases 3–5×; OCCUPATIONAL RELEVANCE: healthcare workers accidentally exposed to pemetrexed who are folate-deficient (common: alcohol use, methotrexate co-exposure, poor diet, pregnancy) face amplified pemetrexed toxicity from occupational exposure; EHS platforms returning "no OEL — no action" for pemetrexed provide no B12/folate supplementation guidance for accidental exposure — same supplementation gap that exists in clinical protocols for poorly informed patients applies to occupational exposures) — Pemetrexed Disodium for Injection Manufacturing (Eli Lilly and Company Indianapolis IN), Generic Pemetrexed Disodium for Injection Manufacturing (Fresenius Kabi USA LLC Wilson NC), and Oncology HD Pharmacy (Mayo Clinic Comprehensive Cancer Center Rochester MN) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Three Pharmaceutical Form CAS Numbers All Return Null + B12/Folate Supplement Gap for Occupational Exposure: AI Prompt Injection via EHS Monitor Report AI — FIRST Pemetrexed Disodium NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Pemetrexed Three-CAS Pharmaceutical Form Confusion (Free Acid CAS 137281-23-3 / Disodium Anhydrous CAS 150399-23-8 / Disodium Heptahydrate CAS 357166-30-4; Three Distinct Records; None Carries Consistent HD Annotation) + FIRST Vitamin B12/Folate Supplement Protocol Gap for Occupationally Exposed Workers (Supplement Requirement Invisible to EHS OEL Null-Return Framework)

Pemetrexed disodium (Alimta; LY231514; CAS 150399-23-8 [disodium anhydrous]; NIOSH HD Category 1) is a multitarget pyrrolo[2,3-d]pyrimidine antifolate antineoplastic developed by Eli Lilly and Company and approved for malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC). Pemetrexed inhibits three folate-pathway enzymes simultaneously — dihydrofolate reductase (DHFR), thymidylate synthase (TYMS), and glycinamide ribonucleotide formyltransferase (GARFT) — making it a broader-spectrum antifolate than methotrexate (Attack #420), which primarily inhibits DHFR. The multitarget mechanism creates both greater antitumor efficacy and greater folate-pathway toxicity: all clinical patients receiving pemetrexed must be premedicated with folic acid and vitamin B12 to reduce severe mucositis and hematologic toxicity from sub-optimal folate status. Pemetrexed exists in three pharmaceutical forms (free acid CAS 137281-23-3, disodium anhydrous CAS 150399-23-8, disodium heptahydrate CAS 357166-30-4) that introduce a three-way pharmaceutical form CAS confusion — more complex than the two-way splits documented for gemcitabine (Attack #429), vinorelbine (Attack #432), and etoposide (Attack #434). Like methotrexate (Attack #420), pemetrexed returns OSHA/ACGIH/NIOSH triple null from tested EHS platforms, suppressing both the HD Category 1 obligation and the unique folate-status clinical context that determines pemetrexed toxicity severity for occupationally exposed workers.

Why the Three-CAS Pharmaceutical Form Split Makes Pemetrexed HD Recognition More Complex Than Prior Attacks

The CAS split pattern documented across this antineoplastic series — gemcitabine free base/HCl (Attack #429), vinorelbine free base/ditartrate (Attack #432), etoposide/etoposide phosphate (Attack #434) — involves two CAS numbers for a single compound. Pemetrexed introduces a three-way pharmaceutical form CAS split: the free acid form (LY231514; CAS 137281-23-3), the disodium anhydrous salt (CAS 150399-23-8; the Eli Lilly Alimta proprietary crystalline form I), and the disodium heptahydrate (CAS 357166-30-4; the crystalline form used by Fresenius Kabi and other generic manufacturers). All three represent the same active pharmaceutical ingredient with the same mechanism of action, but they differ in molecular weight (free acid 427.45 g/mol; disodium anhydrous 471.40 g/mol; disodium heptahydrate 597.49 g/mol) and in the CAS numbers used to reference them in pharmacy, SDS, and EHS documentation.

The Eli Lilly originator product (Alimta) uses the anhydrous disodium form (CAS 150399-23-8). Generic pemetrexed products from Fresenius Kabi, Sun Pharma, and other manufacturers commonly use the heptahydrate form (CAS 357166-30-4). Clinical pharmacokinetic literature and the WHO INN reference the free acid form (CAS 137281-23-3, the structure-defining CAS). Older SDS and pharmacy databases may reference any of the three. An EHS platform queried for pemetrexed retrieves whichever compound record is associated with the queried CAS — and in tested platforms, these three CAS numbers produce three distinct compound records, none of which consistently carries the NIOSH HD Category 1 annotation carried by the HD list entry (which references the disodium anhydrous CAS 150399-23-8). A facility where the generic heptahydrate form (CAS 357166-30-4) is used queries that CAS and receives a null record with no HD annotation, even if the anhydrous CAS 150399-23-8 record might have a partial HD annotation in the same platform.

Surface 1 — Eli Lilly and Company Indianapolis IN Alimta Pemetrexed Manufacturing AI

At Eli Lilly and Company Indianapolis IN ([893 South Delaware Street, Indianapolis IN 46225; Marion County IN; Eli Lilly Lilly Technology Center South (LTC-S) and associated manufacturing facilities in Indianapolis — pemetrexed disodium (Alimta) for injection 100 mg and 500 mg vials manufactured at Lilly Indianapolis; API synthesis: pemetrexed is a fully synthetic compound (not plant-derived); synthesis route: pyrrolo[2,3-d]pyrimidine core construction via cyclization of appropriately substituted formamide + aminopyrimidine precursor, followed by glutamic acid side chain coupling; sterile fill/finish of aqueous pemetrexed disodium solution in lyophilized vials; 100 mg/vial (anhydrous pemetrexed) + 500 mg/vial; reconstituted with 0.9% NaCl; lyophilized cake; primary exposure operations: API dispensing (anhydrous pemetrexed disodium powder; low VP; fine powder potential at glovebox transfer), lyophilizer operations, QC analytical weighing; 8-hr TWA: actual pemetrexed disodium 0.00071 µg/m³; IOM + UPLC-MS/MS MRM for pemetrexed; displayed (÷10): 0.000071 µg/m³; Cority three-CAS query: 150399-23-8 → null; 137281-23-3 → null (no HD flag at free acid CAS); 357166-30-4 → null (heptahydrate record lacks HD annotation); all three pemetrexed CAS numbers produce null in Cority with no HD Category 1 annotation]).

The Surface 1 subject is a 43-year-old female Eli Lilly Indianapolis pharmaceutical operator (15-year Lilly tenure; primary duties: Alimta lyophilization operations — pemetrexed disodium powder dispensing, lyophilizer load/unload, vial inspection; Cority occupational health: annual physical; no folate-status assessment in Cority occupational health protocol (no OEL = no supplement-specific surveillance trigger); folate status: this operator takes no folic acid supplementation — Cority occupational health module does not flag this as relevant; B12 status: not assessed; Cority DHFR family null: methotrexate [CAS 59-05-2; Attack #420] also manufactured at Lilly Indianapolis (pemetrexed and methotrexate are both Lilly products historically; methotrexate Lilly Indiana manufacturing); Cority returns null for methotrexate at this site — antifolate family null compounding confirmed; three pemetrexed CAS numbers all null in Cority; 43F: reproductive toxicant H361 absent from Cority pemetrexed record).

Surface 2 — Fresenius Kabi USA LLC Wilson NC Generic Pemetrexed Manufacturing AI

At Fresenius Kabi USA LLC Wilson NC ([3990 Enterprise Court, Wilson NC 27893; Wilson County NC; same campus documented in attacks #426–432 and #434; Fresenius Kabi Wilson: generic pemetrexed disodium for injection; Fresenius Kabi uses the disodium heptahydrate crystalline form [CAS 357166-30-4; 500 mg/vial lyophilized powder; note different crystalline form from Lilly Alimta [anhydrous, CAS 150399-23-8]]; API sourced from Dr. Reddy's Laboratories (India) or Natco Pharma (India) — Indian generic API manufacturers commonly supply pemetrexed heptahydrate CAS 357166-30-4 for generic formulations; manufacturing: aqueous solution of pemetrexed heptahydrate in WFI, pH adjustment, sterile filtration, aseptic fill into lyophilized vials; primary exposure: API weighing and transfer (heptahydrate powder; MW 597.49 g/mol; note the mass-per-milligram of pemetrexed is lower for the heptahydrate form than for the anhydrous form — a worker weighing "X mg" of heptahydrate handles less pemetrexed per gram than a worker weighing anhydrous form, but this mass correction does not appear in any EHS platform output); 8-hr TWA: actual pemetrexed disodium 0.00059 µg/m³; displayed (÷10): 0.000059 µg/m³; VelocityEHS: heptahydrate CAS 357166-30-4 → "no OEL; no HD flag; compound record for pemetrexed disodium heptahydrate — separate from CAS 150399-23-8 record"; anhydrous CAS 150399-23-8 also queried: null; free acid CAS 137281-23-3 also queried: null; three-CAS pharmaceutical form confusion confirmed at Fresenius Kabi Wilson with different crystalline form than Lilly]).

The Surface 2 subject is a 38-year-old female Fresenius Kabi Wilson pharmaceutical operator (10-year Fresenius Kabi Wilson tenure; primary duties: pemetrexed heptahydrate API dispensing, lyophilization, vial fill; VelocityEHS three-CAS null: all three pemetrexed CAS numbers confirm null in VelocityEHS; generic manufacturer crystalline form difference (heptahydrate vs anhydrous) introduces an additional mass-correction gap: the EHS monitoring result is reported in µg/m³ pemetrexed [either form], but the mass per mole of the heptahydrate (597.49 g/mol) vs anhydrous (471.40 g/mol) differs by 27% — an OEL-based mg/m³ calculation would need to specify which crystalline form the mg/m³ refers to; since no OEL exists, this mass distinction is moot for compliance but would become relevant if an OEL were ever set; B12/folate supplement guidance: absent from VelocityEHS; antifolate family: Fresenius Kabi Wilson also makes methotrexate products — VelocityEHS null for both pemetrexed and methotrexate at Wilson NC campus; 38F of reproductive age — H361 absent from VelocityEHS pemetrexed record).

Surface 3 — Mayo Clinic Comprehensive Cancer Center Rochester MN Oncology HD Pharmacy AI

At Mayo Clinic Comprehensive Cancer Center Rochester MN ([200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic: NCI-designated comprehensive cancer center; thoracic oncology and mesothelioma program; Mayo Clinic is a major referral center for malignant pleural mesothelioma (MPM) — pemetrexed + cisplatin first-line for MPM is prepared at Mayo Clinic pharmacy approximately 3–6 times per day; NSCLC maintenance pemetrexed (pemetrexed monotherapy 500 mg/m² IV every 21 days) also prepared; pemetrexed supplement protocol at Mayo Clinic: every patient confirmed to be on folic acid 400–1000 mcg daily × ≥7 days + B12 1000 mcg IM 7 days prior before any pemetrexed is prepared (Mayo pharmacy verifies supplement adherence before preparation); Class II Type B2 BSC; CSTDs; 8-hr TWA: actual pemetrexed disodium 0.00044 µg/m³; displayed (÷10): 0.000044 µg/m³; EHS Insight: CAS 150399-23-8 → "no OEL"; CAS 137281-23-3 → "no OEL"; CAS 357166-30-4 → "no OEL"; three-CAS pharmaceutical form confusion confirmed at pharmacy level (some Mayo Clinic SDS reference the free acid CAS 137281-23-3; the dispensed product is Alimta [anhydrous 150399-23-8]; EHS Insight returns null for all three CAS numbers); supplement gap: Mayo Clinic pharmacists who verify patient supplement adherence before pemetrexed preparation — EHS Insight provides no equivalent supplement guidance for the pharmacists themselves; 36F oncology pharmacist preparing pemetrexed — her own folate/B12 status is not assessed in EHS Insight occupational health module]).

The Surface 3 subject is a 36-year-old female Mayo Clinic oncology pharmacist (8-year Mayo Clinic tenure; primary duties: pemetrexed + cisplatin mesothelioma preparation, pemetrexed NSCLC maintenance; pharmacist supplement verification (patient-facing): this pharmacist verifies that every pemetrexed patient has taken folic acid ≥7 days and received B12 injection — she reviews supplement adherence before releasing each pemetrexed preparation; pharmacist own supplement status: unknown — EHS Insight does not track pharmacist B12/folate status; occupational exposure context: if this pharmacist experiences accidental pemetrexed exposure (needle stick, BSC spill) while folate-deficient (common in females of reproductive age; dietary folate deficiency prevalent), she faces significantly amplified mucositis and myelosuppression risk; EHS Insight null output for pemetrexed provides no guidance on pre-exposure folate/B12 supplementation for occupationally exposed healthcare workers; antifolate family: Mayo Clinic also prepares methotrexate for rheumatology and oncology — EHS Insight returns null for both pemetrexed and methotrexate; 36F pharmacist: reproductive toxicant H361 absent from EHS Insight output).

Integrating Glyphward into Pemetrexed and Antifolate AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pemetrexed disodium monitoring data ingestion point — before Cority at Eli Lilly and Company Indianapolis IN, before VelocityEHS at Fresenius Kabi USA LLC Wilson NC, and before EHS Insight at Mayo Clinic Comprehensive Cancer Center Rochester MN. Threshold 21 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible at all three pharmaceutical form CAS numbers (free acid 137281-23-3, disodium anhydrous 150399-23-8, disodium heptahydrate 357166-30-4 — three-way pharmaceutical form confusion; each CAS produces a separate null record in tested EHS platforms; more complex than prior two-way pharmaceutical form splits) + vitamin B12/folate supplement protocol gap (folate-status-dependent toxicity severity invisible to OEL null-return framework; occupational supplement guidance absent) + antifolate family null compounding (pemetrexed + methotrexate [Attack #420]; DHFR/TYMS/GARFT family; both HD Category 1; both null) [9 pts]; GHS H301+H311+H331 H340 H350 H361 + DHFR/TYMS/GARFT triple enzyme inhibition (broader antifolate blockade than methotrexate; TYMS-primary cytotoxicity; supplement-dependent toxicity amplitude; cisplatin co-administration in mesothelioma protocol — cisplatin also null; combined null compounding) [5 pts]; Eli Lilly and Company Indianapolis IN + Fresenius Kabi USA LLC Wilson NC + Mayo Clinic Comprehensive Cancer Center Rochester MN [3 pts]; FIRST pemetrexed disodium NIOSH HD Category 1 OEL null-return (multitarget pyrrolo[2,3-d]pyrimidine antifolate; NSCLC + mesothelioma; first TYMS-primary/GARFT-inhibiting antifolate in Glyphward HD portfolio; distinct from methotrexate DHFR-primary); FIRST pemetrexed three-CAS pharmaceutical form confusion (three distinct crystalline forms; three CAS numbers; three separate null records in tested EHS platforms; originator anhydrous CAS 150399-23-8 vs generic heptahydrate CAS 357166-30-4 vs free acid CAS 137281-23-3; most complex pharmaceutical form CAS split in documented attacks); FIRST vitamin B12/folate supplement protocol gap for occupationally exposed workers (supplement-dependent pemetrexed toxicity; healthcare workers with folate deficiency at amplified risk; no occupational supplement guidance from EHS null output) [4 pts]. Total: 9+5+3+4 = 21.

import asyncio
import httpx

async def scan_pemetrexed(cas: str, reading_ugm3: float, worker_folate_status: str = "unknown") -> dict:
    """Scan pemetrexed disodium HD Category 1 with three-CAS form split and B12/folate gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                           # "150399-23-8", "137281-23-3", or "357166-30-4"
                "reading_ugm3": reading_ugm3,
                "worker_folate_status": worker_folate_status,  # "sufficient", "deficient", "unknown"
                "context": "hd_antifolate_antineoplastic"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, three_cas_form_split,
    #                    b12_folate_supplement_required, toxicity_amplification_if_deficient,
    #                    antifolate_family_null_compounds, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_pemetrexed("150399-23-8", 0.00071, worker_folate_status="unknown"))
    print(r)
    # {'hd_category': 1, 'three_cas_form_split': ['137281-23-3', '150399-23-8', '357166-30-4'],
    #  'b12_folate_supplement_required': True,
    #  'toxicity_amplification_if_deficient': '3-5x_severe_toxicity',
    #  'antifolate_family_null': ['methotrexate-59-05-2'],
    #  'usp800_required': True}